Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from BioInvent International AB ( (SE:BINV) ).
BioInvent International will host two Key Opinion Leader events to showcase scientific and clinical advances in its oncology portfolio, particularly the anti-TNFR2 antibody BI-1808 and the anti-FcγRIIB antibody BI-1206. The initiatives aim to deepen investor and clinician understanding of the company’s solid tumor and hematology programs, ahead of key ASCO and EHA data disclosures, reinforcing BioInvent’s positioning in next-generation immuno-oncology.
A virtual event on May 27 will focus on BI-1808’s potential in treating ovarian cancer and other solid tumors, featuring expert commentary on targeting TNFR2 in the evolving treatment landscape. A second, hybrid lunch briefing in Stockholm on June 11, held alongside the EHA 2026 Congress, will highlight BI-1808 in cutaneous T-cell lymphoma and BI-1206 in non-Hodgkin lymphoma, aligning BioInvent’s scientific narrative with emerging conference data.
Through these tightly timed events around major oncology meetings, BioInvent seeks to raise visibility of its lead assets and underline the breadth of its immuno-oncology approach. The outreach may support stakeholder engagement, inform future partnering discussions, and potentially influence market perception as new clinical data emerge for its antibody programs.
The most recent analyst rating on (SE:BINV) stock is a Buy with a SEK90.00 price target. To see the full list of analyst forecasts on BioInvent International AB stock, see the SE:BINV Stock Forecast page.
More about BioInvent International AB
BioInvent International AB is a Swedish clinical-stage biotechnology company focused on discovering and developing first-in-class immuno-modulatory antibodies for cancer therapy. Its pipeline targets both hematological malignancies and solid tumors, supported by the proprietary F.I.R.S.T. discovery platform and revenue-generating collaborations and manufacturing for top-tier pharmaceutical partners.
Average Trading Volume: 99,739
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.45B
For detailed information about BINV stock, go to TipRanks’ Stock Analysis page.